KRAS Glycine-to-Cysteine Mutant Protein (KRAS G12C)

KRAS G12C is a mutant form of the KRAS protein, a small GTPase that acts as a molecular switch in cell signaling pathways controlling proliferation, survival, and differentiation. The "G12C" mutation refers to the substitution of glycine (G) with cysteine (C) at codon 12. This specific mutation is highly prevalent in certain cancers, especially lung adenocarcinoma. The G12C mutation impairs GAP-mediated hydrolysis, resulting in constitutive activation. Recent advances have led to the development of selective covalent inhibitors that bind specifically to the cysteine introduced by this mutation, offering a targeted therapeutic approach.

Other names

KRAS G12C MutantKRAS G12CKRAS(G12C)

Covalent binding to cysteine residue at position 12, locking KRAS in inactive GDP-bound state.